Recruiting
Phase 1
Phase 2

HSV-tk & Valacyclovir

Sponsor:

The Methodist Hospital Research Institute

Code:

NCT01913106

Conditions

Prostatic Neoplasms

Eligibility Criteria

Sex: Male

Age: 0+

Healthy Volunteers: Not accepted

Interventions

HSV-tk +Valacyclovir in Combination with Brachytherapy

Study Details

Brief summary:

The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully impact on the development of metastatic disease and the control of preexisting metastasis.

Conditions

Prostatic Neoplasms

Study ID

NCT01913106

Start date

Jun, 2007

Status verified date

Jun, 2016

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2018

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 0+

Healthy Volunteers: Not accepted

INCLUSION CRITERIA:

  • biopsy-proven local recurrence of prostate cancer without metastatic disease after the hormone therapy at least 2 year after the completion of definitive radiation therapy
  • Zubrod performance status 0-1
  • WBC ≥ 4,000/μl, platelets ≥ 100,000/μl
  • hemoglobin ≥ 8.5 mg/dl
  • normal partial thromboplastin time and prothrombin time
  • bilirubin < 1.5 mg/dl, and AST and alanine aminotransferase < 2.5 times the upper limit of normal
  • Serum creatinine ≤ 1.6 mg/dl
  • Must undergo pre-treatment evaluation of tumor extent and tumor measurement
  • Nutritional and general physical condition must be considered compatible with the proposed radio-therapeutic treatment
  • Not on any other experimental therapeutic cancer treatment
  • No active untreated infection
  • No major medical or psychiatric illness
  • International Prostate Symptom Score (IPSS) less than 15
  • Signed study-specific consent form prior to study entry
  • Prostate volume less than 50 cc
  • PSA > 10ng/ml within the past 3 months may enter study

EXCLUSION CRITERIA:

  • Symptomatic metastasis disease
  • Patients with a life expectancy < 10 years
  • Patients on corticosteroids or any immunosuppressive drugs.
  • HIV + patients
  • Patients with acute infections (viral, bacterial, or fungal infections requiring therapy)
  • Patients with cirrhosis.
  • Patients with collagen vascular diseases
  • International Prostate Symptom Score (IPSS) greater than 15
  • Prostate volume greater than 50 cc
  • Second active cancer except cutaneous cancer
  • Patients with history of allergies to valacyclovir, acyclovier or who cannot take oral pills

Study Design

Enrollment

25 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: HSV-tk + Valacyclovir and Brachytherapy

You will be given an antibiotic (Ciproflaxin) to take twice a day beginning the day before the procedure, and continuing for a total of 3 - 5 days. You will also be given 4 pills called (Valtrex) valacyclovir to take three times a day for 14 days, beginning the day before the procedure. You will be given a pill diary in which you will record each dose of valacyclovir that you take. You will receive brachytherapy (radioactive seed placement) the day after you begin taking your pills. After the radioactive seeds are placed, while you are still in the operating room, you will receive an injection into your prostate of 1 or 2 ml (one-fifth or two-fifths of a teaspoon) of a solution of the vector carrying the gene.

Interventions

HSV-tk +Valacyclovir in Combination with Brachytherapy

The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or "vehicle" to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein.

Primary outcome measure

  • 1. Safety based on standard laboratory and clinical adverse event monitoring [ Time Frame: 5-year biochemical disease free survival rate ]

Central Contacts and Locations

Central contacts

Brent Bell, PA-C

713-394-1105bcbell@houstonmethodist.org

Brian Butler, MD

ebutler@houstonmethodist.org

Locations

Houston Methodist

Recruiting

Houston, Texas, United States, 77030

Contacts

Brent Bell, PA-C

713-394-1105bcbell@tmhs.org

Edward B Butler, MD

ebutler@tmhs.org

Principal Investigator:

Edward B Butler, MD

More Information

Sponsor

The Methodist Hospital Research Institute

Last update posted

Jul 1, 2016

Last verified

Jun, 2016

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by The Methodist Hospital Research Institute on 2016-07-01.